Jiangxi Boya Bio-Pharmaceutical Co Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Jiangxi Boya Bio-Pharmaceutical Co Ltd with three other
companies in this sector in China:
Zhongyuan Union Cell & Gene Engineering Corp Ltd
sales of 835.64 million Chinese Renmimbi [US$123.43 million]
of which 61%
was Scientific research service),
Tianjin Ringpu Bio-Technology Co Ltd
(969.68 million Chinese Renmimbi [US$143.23 million]
of which 63%
was Veterinary Biological Products), and
Beijing SL Pharmaceutical Co Ltd
(1.01 billion Chinese Renmimbi [US$149.16 million]
of which 98%
was Pharmaceuticals Industry).
During the year ended December of 2016, sales at
Jiangxi Boya Bio-Pharmaceutical Co Ltd were 946.57 million Chinese Renmimbi (US$139.82 million).
increase of 74.3%
versus 2015, when the company's sales were 543.10 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Jiangxi Boya Bio-Pharmaceutical Co Ltd
(and since 2011, sales have increased a total of 381%).
Sales of Bio-Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
1,065.6% in 2016, from
18.56 million Chinese Renmimbi to 216.29 million Chinese Renmimbi.